SCHEMBL22232187

SCHEMBL22232187

COc1cc(N)c(C)c(Cc2ccccc2C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
IDO1 P14902 2/20 0.43
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
CYP27A1 Q02318 1/20 0.40
CYP24A1 Q07973 1/20 0.40
GAA P10253 1/20 0.39
EPHX2 P34913 1/20 0.38
MAOB P27338 2/20 0.38
KCNH2 Q12809 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
ACP1 P24666 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22231903 0.81 IDO1 (0.39) ALDH1A1TDP1KMT2AMEN1IDO1
SCHEMBL22231824 0.81 IDO1 (0.42) ALDH1A1TDP1KDM4EIDO1GAA
SCHEMBL29454268 0.81 IDO1 (0.39) ALDH1A1TDP1KMT2AMEN1IDO1
SCHEMBL22232411 0.81 GRIN2B (0.39) HTTMAPTGAAKCNH2SLC6A2
SCHEMBL22231752 0.81 CNR2 (0.43) ALDH1A1KMT2AMEN1MAPTCYP24A1
SCHEMBL22231732 0.80 IDO1 (0.41) ALDH1A1TDP1KDM4EKMT2AMEN1
SCHEMBL22232195 0.80 ADORA2A (0.42) ALDH1A1KDM4EHTTKMT2AMEN1
SCHEMBL22232089 0.78 CNR2 (0.41) ALDH1A1KDM4EIDO1SLC6A2SLC6A4
SCHEMBL29454340 0.78 CNR2 (0.41) ALDH1A1KDM4EIDO1SLC6A2SLC6A4
SCHEMBL22232329 0.76 LTA4H (0.50) ALDH1A1KMT2AMEN1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP claimed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP disclosed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS ALDH1A1 1020/4885TDP1 1133/4885KDM4E 748/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS ALDH1A1 2035/4885TDP1 3645/4885KDM4E 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.